Background: Multiple sclerosis (MS) is the most prevalent neurological disability of young adults. Anti-inflammatory drugs have relative effects on MS. The anti-inflammatory and antioxidative effects of Zingiber officinale (ginger) have been proven in some experimental and clinical investigations. The aim of this study was to evaluate the effects of ginger extract on preventing myelin degradation in a rat model of MS. Methods: Forty nine male Wistar rats were used in this study and divided into four control groups: the normal group, cuprizone-induced group, sham group (cuprizone [CPZ] + sodium carboxymethyl cellulose [NaCMC]), standard control group (fingolimod + cuprizone), including three experimental groups of CPZ, each receiving three different doses of ginger extract: 150, 300, and 600mg/kg /kg/day. Results: Ginger extract of 600 mg/kg prevented corpus callosum from demyelination; however, a significant difference was observed in the fingolimod group (p < 0.05). Difference in the CPZ group was quite significant (p < 0.05). Conclusion: Treatment with ginger inhibited demyelination and alleviated remyelination of corpus callosum in rats. Therefore, it could serve as a therapeutic agent in the MS.
Background: Multiple sclerosis (MS) is the most prevalent neurological disability of young adults. Anti-inflammatory drugs have relative effects on MS. The anti-inflammatory and antioxidative effects of Zingiber officinale (ginger) have been proven in some experimental and clinical investigations. The aim of this study was to evaluate the effects of ginger extract on preventing myelin degradation in a rat model of MS. Methods: Forty nine male Wistar rats were used in this study and divided into four control groups: the normal group, cuprizone-induced group, sham group (cuprizone [CPZ] + sodium carboxymethyl cellulose [NaCMC]), standard control group (fingolimod + cuprizone), including three experimental groups of CPZ, each receiving three different doses of ginger extract: 150, 300, and 600mg/kg /kg/day. Results: Ginger extract of 600 mg/kg prevented corpus callosum from demyelination; however, a significant difference was observed in the fingolimod group (p < 0.05). Difference in the CPZ group was quite significant (p < 0.05). Conclusion: Treatment with ginger inhibited demyelination and alleviated remyelination of corpus callosum in rats. Therefore, it could serve as a therapeutic agent in the MS.
Entities:
Keywords:
Corpus callosum; Demyelination; Ginger extract; Multiple sclerosis; Rat
Multiple sclerosis is a chronic neurological disorder of the CNS that causes damage to the axonal myelin sheath[1,2]. After myelin degradation, numerous plaques are formed around nerve fibers and the lack of myelin leads to disturbances in the direction of neural impulses[3,4]. On average, five persons out of every 100,000 people are diagnosed with this disease worldwide[5]. The neuropathic disorder is more common among young people, with a high prevalence in women than men[6,7].More than 2.5 million people are affected by MS all over the world, with an increasing trend at an alarming rate[8]. In many countries, especially Western societies, MS is the main risk factor of disability[9]. It has been discovered that both environmental and genetic factors play a role in the prevalence and geographical dispersion of this disease[10,11]. The exact mechanism of neuronal loss remains a challenge for the scientific community and is still unclear[12].MS is a chronic inflammatory, demyelinating and neurodegenerative disorder[13,14]. Inflammation in the CNS is induced by the entry of lymphocytes. T cells secrete proinflammatory molecules that increase the permeability of the BBB and the entrance of other immune cells[15]. There is no effective clinical treatment or therapy for MS disease till date[16,17]. The available medications have been shown to be associated with many side effects, including headaches, back pain, macular edema, high risk of serious infections, diarrhea, hair thinning, and so forth[18]. Medicinal plants have long been used for therapeutic purposes[19,20], and according to the World Health Organization approximates, 80% of the world’s population tends to use herbal medicines[21].Zingier officinale Roscoe (Ginger) is a tropical and subtropical plant that is widely used as a spice[22] and is native to Southeastern Asia. Ginger has been used for thousands of years for the treatment of numerous diseases[23] or as an antiemetic[24]. It has analgesic[25], antitumor[26], antioxidant, and anti-inflammatory impacts[27]. Ginger has several effective ingredients, including gingerols, shogaols, and some phenolic ketone derivatives[28]. Among the ginger compounds, 6-gingerol has been demonstrated to modulate neuroinflammation and prevent cognitive impairment in animal models[29]. In addition, this compound has significant potential as a novel anti‐inflammatory agent for treating autoimmune diseases via direct modulatory effects on dendritic cells[30]. Treatment of EAE mice with ginger extract downregulates the expression of inflammatory chemokines[31]. As a result, in patients with Alzheimer’s and other neurological diseases, 6-Shogaol might improve the symptoms of the diseases[32,33]. In addition, neuroprotective effects of 6-Shogaol and its metabolite in the remyelination of the spinal cord have been reported in an MS model, as well[2].Considering the use of nutritional therapy and medicinal properties of ginger, especially its anti-inflammatory properties, this study aimed to evaluate the effect of ginger extract on preventing myelin degradation in a rat model of the MS. Additionally, the effect of ginger extract on MS was compared with fingolimod, which is used for the treatment of MS.
Total phenolic measurement standardized extract yGalic acid standard curve was plotted in the concentration range of 0.5-5 μg/mL. The regression equation was expressed as y = 0.0649x + 0.0168, where yaxis indicates OD absorption, and x axis represents GAE phenol content in the sample (μg/mL) with the correlation factor of r² = 0.9921. The lyophilized extract powder was standardized to have 8.18 ± 1.61% mg GAE /100 mg (Fig. 1).Rat behavioral test results improved after ginger treatmentThe results obtained from the basket test showed that the falling down time of the basket wall increased more in ginger-treated groups that in the CPZ groups (p ˂ 0.01; Fig. 2). The high dose of ginger extract improved the falling down time but showed no significant difference in relation to the first group. The high dose of extract was more effective than fingolimod; however, there was no significant difference between them. According to Figure 2, the latency time to fall in the CPZ and sham groups significantly decreased in comparison to the experimental groups. In the group treated with the high dose of extract, the latency increased significantly, and there was no significant difference between this group and the control group.Extract of ginger
and fingolimod improved remyelinationTEM revealed an increased thickness of myelinated axons in the CC in the high-dose extract group compared to the CPZ group (p < 0.05). The CUP group, sham group, and Fingolimod group showed no statistically significant difference, in relation to increase thickness of myelinated axons as observed in the control group. There was also no significant difference between the groups receiving high-dose extract and fingolimod (Fig. 3). Figure 3a displays the TEM of the CC of the rats’ brains in the studied groups. The demyelination of the CPZ group can be observed. In the high dose of the ginger extract group, remyelination was done properly (TEM 2000×). As Figure 3b shows, the thickness of myelin in the fingolimod and high-dose extract groups increased significantly compared with the CPZ and sham groups.Comparison of the basket test results of the effect of ginger extract groups with different studied groups. The figure shows that the latency to fall in all the CPZ groups significantly reduced compared to the control groups (p < 0.001). In groups treated with fingolimod and a high dose of Zingiber officinale extract, the latency significantly increased (p < 0.001). Control group (Cont.), CUP group, Sham group, fingolimod group (Fing); ExL, ExM, and ExH, Zingiber officinale extract groups (150, 300, and 600 mg/kg/day, respectively; *Significant difference with the control group; #significant difference with the CPZ and sham groups.The expression of
M
and Olig2 genes
increased in treatment groupsThe results showed that the CPZ gavage caused a significant reduction (p < 0.001) in the Mbp gene expression in rats with MS. The high dose of ginger extract and fingolimod consumption significantly (p < 0.001) increased the Mbp expression level in treatment groups than in the CPZ groups, five weeks after administration. Medium and low doses of ginger increased the Mbp expression level; nonetheless, no statistical difference was observed between the mentioned doses. In all experimental groups, the Mbp gene expression increased in comparison to the CPZ and sham groups (Fig. 4A). There was no significant difference between the high-dose extract and fingolimod groups. The expression levels of Olig2 in all treatment groups were significantly (p < 0.05) higher than the CPZ group. In the current study, the Olig2 expression level increased in the fingolimod and the high dose of extract groups; however, it was statistically significant (p < 0.05) compared to the control group. Figure 4B shows the Olig2 gene expression level in the studied groups. In all experimental groups, the olig2 gene expression increased, except for the CPZ and sham groups. There was no significant difference between the high dose of ginger extract and the fingolimod groups.MBP and Olig2
protein levels increased in treatment groupsThe direct competitive ELISA technique was used to measure the protein level of MBP. In this method, OD has an inverse relationship with the antigen level of this protein. In the fingolimod group, the protein level of MBP increased and showed a difference from the control group. Also, the high-dose extract group indicated an increase in the protein level of MBP; however, it had no significant difference with the fingolimod group. Regarding the level of OD for MBP protein in groups, there was no significant difference between the fingolimod and high-dose extract groups (Fig. 5A). However, there was a significant difference between the treatment groups (fingolimod and a high dose of ginger extract) and CPZ groups. An indirect competitive ELISA technique was used to measure the protein level of Olig2. In this method, the OD has a direct relation with the amount of antigen. Accordingly, the level of Olig2 protein increased in all treated groups, except for the CPZ group. There were no significant differences between the three treatment groups of ginger extract. Regarding the level of OD for Olig2 protein in the groups, there was no significant difference between the fingolimod, high dose of ginger extract, and control groups (Figure 5B). However, there was a significant difference between the CPZ groups.
DISCUSSION
MS is one of the most common neurological disorders in young people[36]. Inflammation and demyelination of the CNS are two main pathological events in MS[37]. Demyelinating diseases, such as MS, can be induced in the CNS of laboratory animals in different ways; for instance, toxin-induced demyelination[38], EAE[39,40], and virus-induced demyelination[41,42]. CPZ is a copper-chelating agent when administrated orally causes extensive demyelination in white or gray matter in the CNS. The demyelination induced by CPZ depends on unremitting exposure[43,44].In the current study, CPZ was administered daily by oral gavage for four weeks to induce the MS model. Based on the results obtained by the electron microscopy and behavioral test, this model was well established in rats. Several studies have focused on different approaches to improve myelination, such as targeting specific signaling pathways, stem cell therapy, suppressing the inflammation process, and the reprogramming of glial cells to oligodendrocyte precursor cells[45]. Different drugs, such as glatiramer acetate, natalizumab, alemtuzumab, and fingolimod are currently used to cure MS[46], which are relatively effective and their adverse effects make them unsuitable for prolonged use[47]. There is still no definitive cure for MS; therefore, trying to find an efficient and safe treatment seems to be essential[48].Transmission electron micrographs of CC of rats and the graph of myelin thickness of the studied groups. (A) Effect of ginger extract on remyelination of CC of the rats’ brains. The images was obtained by the TEM from the CC in the studied groups. Demyelination in the CPZ and sham groups, as well as the destruction of the demyelinated axons (DA) and vacuole formation (V) can be observed. In the ExH group, remyelination is performed properly (TEM 2000×). (B) The mean± SE of the thickness of myelin in the studied groups. Control group (Cont.), CUP group, sham group, Fingolimod group (Fing), fingolimod group; ExL, ExM, and ExH, Zingiber officinale extract groups (150, 300, and 600 mg/kg/day, respectively; The thickness of myelin in the fingolimod and ExH groups increased significantly compared to the CPZ and sham groups. *Significant difference with the control group (p < 0.05); #significant difference with the CPZ and sham groups (p < 0.05).Effect of ginger extract on expression levels of Mbp (A) and Olig2 (B) genes. The figure shows mean ± SE of the gene expression levels in CC of studied groups. The expression levels of Mbp and Olig2 genes in the Zingiber officinale extract group (ExH) and fingolimod (Fing) groups significantly increased compared to other groups. Control group(Cont.), CUP group, sham group, fingolimod group (Fing); ExL, ExM, and ExH, Zingiber officinale extract groups (150, 300, and 600 mg/kg/day, respectively *Significant difference with the control group; #Significant difference with the CPZ and sham groups.Over the last decade, alternative therapies for treating MS, especially herbal medicine, have noticeably been used in MS patients[49,50]. Today, several research trials have revealed that ginger and its bioactive components have antioxidant[51,52] and neuro-protective[32] effects. Ginger is used by MS patients due to its antiinflammatory activity[53]. In this study, the effect of different doses of extract of ginger was investigated on MS rat models and compared with the fingolimod group, in order to assess the effectiveness of ginger In a rat model of MS.The present study found that the potential therapeutic effect of ginger extract at a dose of 600 mg/kg could prevent axonal demyelination in CC. There was no meaningful difference between the control and standard (fingolimod) groups, whereas a significant difference was observed between the CPZ-induced MS and experimental (600 mg/kg) groups. Medium and low doses of ginger extract also showed the same effects; however, these effects were not statistically significant.Effect of ginger extract on MBP (A) and Olig2 (B) protein levels. The OD of MBP and Olig2 protein in groups showed a significant difference between fingolimod and the high-dose of Zingiber officinale extract group and the CPZ and sham groups. Control group (Cont.), CUP group, sham group, Fingolimod group (Fing), ExL, ExM, and ExH, Zingiber officinale extract groups (150, 300, and 600 mg/kg/day, respectively; *Significant difference with the control group; #significant difference with the CPZ and sham groups. *: Significant difference with the control group. #: Significant difference with CPZ and sham groups.In the electron microscopic study, the high dose of ginger extract significantly protected the myelin sheath degeneration, which was confirmed by the behavioral test and reverse transcription-polymerase chain reaction and ELISA methods. Similar to our findings, Rittchen et al.[54] indicated the useful and beneficial effects of ginger compounds in a vast range of inflammatory disorders, such as MS. Nanotherapy-based delivery of leukemia inhibitory factor directly to oligodendrocyte precursor cells proved to be highly potent in promoting myelin repair in vivo. This study revealed a novel approach of delivering drugs, which can lead to myelin repair in neuronal diseases[54]. Jafarzadeh et al.[53] have reported the effectiveness of ginger on the immunological and inflammatory conditions in EAE. El-Akabawy and El-Kholy[55] studied diabetes-induced CNS damage[55] and exhibited that ginger had a potential therapeutic effect on this neuronal damage. Mehdizadeh
et al.[56] have demonstrated that ginger treatment can increase the number of neuronal cells experiencing MDMA-induced neurotoxicity. Also, the downregulation of Bcl-2 and upregulation of Bax were observed in ginger groups[56]. Gaire et al.[57] have displayed that ginger compounds, such as 6-paradol, effectively protect the brain after cerebral ischemia, likely by attenuating neuroinflammation.In conclusion, our findings provide evidence that the administration of ginger extract prevents demyelination and improves remyelination in the CNS. Therefore, the ameliorative effect of Zingiber officinale extract, and its underlying mechanism of protective effect against some neurodegenerative diseases can play a role as a therapeutic agent in the management of MS.
Acknowledgments
This study was extracted from a Ph.D. thesis by Valiollah Moradi in the Anatomical Science & Cell Biology Department. We are grateful to Prof. Masoud Etemadifar in Isfahan MS Research Center. We also thank the Deputy for Research of Isfahan University of Medical Sciences for supporting the research (Grant No.: 395262).
Ethical statement
This research was approved by the Ethical Committee of Isfahan University of Medical Sciences (Ethics code: IR.MUI.REC.1395.3.262).
Data availability
The data and materials of the study are available from the corresponding author on reasonable request.
Author contributions
VM: contributed to conception and design of the experiment, performed all experiments, analyzed the data, and wrote, supervised and edited the manuscript; EE: contributed to conception and design of the experiment, helped complete all the experiments, and wrote, supervised and edited the manuscript; MG: helped to complete all the experiments; NG: helped to complete all the experiments; BR helped to complete all the experiments. All authors read and approved the final manuscript.
Conflict of interest
None declared.
Funding/support
The research was supported by Isfahan University of medical sciences, Isfahan, Iran.
Authors: J Dörr; A Bitsch; K J G Schmailzl; A Chan; N von Ahsen; M Hummel; R Varon; C M Lill; H-P Vogel; F Zipp; Friedemann Paul Journal: Neurology Date: 2009-09-22 Impact factor: 9.910
Authors: A Jafarzadeh; M Mohammadi-Kordkhayli; R Ahangar-Parvin; V Azizi; H Khoramdel-Azad; A Shamsizadeh; A Ayoobi; M Nemati; Z M Hassan; S M Moazeni; M Khaksari Journal: J Neuroimmunol Date: 2014-08-19 Impact factor: 3.478